National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study
Publication Date
2022Metadata
Show full item recordAbstract/
Currently available live, oral rotavirus vaccines (LORVs) have significantly reduced severe rotavirus hospitalizations and deaths worldwide. However, LORVs are not as effective in low- and middle-income countries (LMIC) where rotavirus disease burden is highest. Next-generation rotavirus vaccine (NGRV) candidates in development may have a greater public health impact where they are needed most. The feasibility and acceptability of possible new rotavirus vaccines were explored as part of a larger public health value proposition for injectable NGRVs in LMICs.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
(Elsevier, 2015)Background The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antibodies associated with the prevention of Plasmodium falciparum infection. We assessed the association between anti-circumsporo ... -
Correction: Costs of continuing RTS, S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries
(Public Library of Science, 2021)Cost estimates under additional vaccine price assumptions are not included in the main result Table (Table 3). Please view S4 Table,“Unit cost of continuing to vaccinate in pilot areas at various vaccine prices,” for results ... -
Costs of continuing RTS, S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries
(Public Library of Science, 2021-01-11)The RTS,S/ASO1E malaria vaccine is being piloted in three countries—Ghana, Kenya, and Malawi—as part of a coordinated evaluation led by the World Health Organization, with support from global partners. This study estimates ...